NCT06917911View on ClinicalTrials.gov

"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, 7+3) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)"

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

November 20, 2025

Primary Completion Date

July 20, 2028

Study Completion Date

July 20, 2028

Conditions

Core Binding Factor Acute Myeloid Leukemia

Interventions

PROCEDURE

Biospecimen Collection

Undergo optional buccal cell collection and/or blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

PROCEDURE

Echocardiography Test

Undergo echocardiography

DRUG

Gemtuzumab Ozogamicin

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

DRUG

Venetoclax

Given PO

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT06917911 - "Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, 7+3) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)" | Biotech Hunter | Biotech Hunter